Clinical value of whole-body PET/CT in patients with active rheumatic diseases. - Wikidata - awgldk - TriplyDB

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

http://www.wikidata.org/entity/Q34896837

about

Fludeoxyglucose positron emission tomography-computed tomography scan showing polyarthritis in a patient with an atypical presentation of Henoch-Schönlein vasculitis without clinical signs of arthritis: a case report.18F-FDG PET/CT for identifying the potential causes and extent of secondary hemophagocytic lymphohistiocytosis Association of Remitting Seronegative Symmetrical Synovitis with Pitting Edema, Polymyalgia Rheumatica, and Adenocarcinoma of the Prostate Multiple values of (18)F-FDG PET/CT in idiopathic inflammatory myopathy.Treatment of adult-onset still's disease: up to date.18F-FDG PET/CT in polymyalgia rheumatica-a pictorial review.The clinical utility of splenic fluorodeoxyglucose uptake for diagnosis and prognosis in patients with macrophage activation syndrome."To be or not to be" for PET in rheumatology. A marriage of love or of convenience?Quantitative Metabolic Volumetric Product on 18Fluorine-2fluoro-2-deoxy-D-glucose-positron Emission Tomography/Computed Tomography in Assessing Treatment Response to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Multiparametric Anal Utility and drawbacks of [18]F-fluorodeoxyglucose positron emission tomography in the evaluation of adult-onset Still's disease.Positron Emission Tomography as an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis.Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study.Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.

P2860

Q36960661-D21166C2-1BCF-47DD-A72D-A41FED4275CD Q37249815-13BC0669-9957-4F62-B1EC-A9A8048326AE Q38285371-24D660D1-2E41-4BA2-987C-2CAD19B30747 Q38613068-BF899FD6-7EC1-4009-BB12-9E6FBB06EA2F Q38679486-AC509A72-5215-4B9F-91B6-BB74F2042255 Q39309315-C9D063D1-E93D-49FB-8068-7B7D69AB8DA8 Q40082328-7B1EC9B2-E07A-4952-BDE9-A53CB3423018 Q42367054-CDBFAD4A-DB86-4369-A6CF-83C4824545BF Q42376463-B2C2ED94-A0FB-4E46-BE6B-561D588E6635 Q45407846-B11BDBCC-9A31-46CA-8008-2290C32F1152 Q47836073-273A2E67-19E1-49BA-B8B0-E0E83294EC6E Q52983436-EEFE0498-C35F-48A5-8C47-6EAF0916E033 Q52985774-C92A2DB5-D2CB-4DEF-8725-6B5A008B0BC4

P2860

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

http://www.wikidata.org/entity/Q34896837

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

@ast

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

@en

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

@nl

type

label

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

@ast

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

@en

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

@nl

prefLabel

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

@ast

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

@en

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

@nl

P1433

Q34896837-10FBE9F6-455A-479A-8E16-9B487CDD4F9D

P1476

Q34896837-A3EEE2E2-0F39-4E8D-A36A-F9528C15853A

P2093

Q34896837-258B8E96-9BD4-4AAD-9E3F-DCDFFA9DE8DE

Q34896837-28DF1B28-D49A-4132-A6CB-92A85E239DB1

Q34896837-A27B99C4-D471-4306-B0C4-6115A7A45FB7

P275

Q34896837-BFB38180-C055-4127-8A74-2FCB7CD232DD

P2860

Q34896837-003D153E-B316-44D1-AB71-73E052BADE63

Q34896837-061C8624-84DA-42AC-B4C5-6B3DCB9E7F32

Q34896837-06F367D1-BB4F-4507-92E1-B1EEB27AE189

Q34896837-07D09167-AFB6-4CF2-8D81-084551B02B84

Q34896837-0A8D8E54-A393-4DC7-B6E0-5C5FF69F5954

Q34896837-0D267CFE-A938-43A8-9E04-5582A0A8AAD2

Q34896837-17EE101B-00B9-4E3C-B02C-F2C1A6AB2518

Q34896837-19DC8F72-E898-47FB-8CC9-D005E4EAC69A

Q34896837-1CB7B773-072B-4A19-854B-A0FE45EA554B

Q34896837-281217E6-A6A8-40FA-9C8C-546AC73D4480

P2888

Q34896837-9AC0882A-28CD-4070-B406-856D799B257E

P304

Q34896837-8EAFEABD-A081-43CF-8584-C7817A486C3A

P31

Q34896837-339C41C2-8559-4F3D-9BF8-50F5B308C97E

Q34896837-A00E1675-4871-429D-8C42-D528662487B3

P356

Q34896837-7009E7A8-46C3-4B10-8033-8ED30A08F817

P433

Q34896837-CB996A21-5B55-4864-843B-87F34D9A782C

P478

Q34896837-4B27C472-C093-4844-A6A3-52F5197756BB

P577

Q34896837-ACE739F6-9BEB-4EFF-9B96-2AD44D22AA83

P5875

Q34896837-2A267962-1376-436A-865B-8DB79E0D0AC5

P6179

Q34896837-988CBA47-A2BE-4A96-A153-B4B1CDD94B5C

P698

Q34896837-CF28DEEB-B96B-4238-867B-960BFB537056

P921

Q34896837-50B96A3D-7441-4305-BFD9-2990532E2E13

P932

Q34896837-6E911672-4557-4D61-904F-68C99F433034

P356

S13075-014-0423-2

P1433

Arthritis Research and Therapy

P1476

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

@en

P2093

Akio Mimori

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Yamashita

http://www.w3.org/2001/XMLSchema#string

Kazuo Kubota

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Utility of fluorodeoxyglucose positron emission tomography/computed tomography for early diagnosis and evaluation of disease activity of relapsing polychondritis: a case series and literature review

HIF-1alpha is essential for myeloid cell-mediated inflammation

Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients.

A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details.

Magnetic resonance angiography in extracranial giant cell arteritis

Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study.

Seronegative spondyloarthropathies: to lump or split?

2-Deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis.

Potential of (18)F-FDG-PET as a valuable adjunct to clinical and response assessment in rheumatoid arthritis and seronegative spondyloarthropathies.

Evaluation of Wegener's granulomatosis using 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

P2888

s13075-014-0423-2

P304

423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13075-014-0423-2

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270758495

http://www.w3.org/2001/XMLSchema#string

P6179

1049058267

http://www.w3.org/2001/XMLSchema#string

P698

25606590

http://www.w3.org/2001/XMLSchema#string

P921

multimodal imaging

P932

4289312

http://www.w3.org/2001/XMLSchema#string